drugset / Trial / NCT00121095

Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer

NCT00121095

Phase 1/2 Unknown 69 enrolled Cytogen Corporation
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety, tolerability and anti-tumor effects of treatment with samarium Sm-153 lexidronam in combination with docetaxel in patients with castrate metastatic prostate cancer.

Timeline

Start
2005-07
Primary completion
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject 153 Sm-EDTMP Unknown 1 unknown
Subject Docetaxel Small molecule 75 mg/m2

Indications